Comparing watch-and-wait and surgery for certain gastrointestinal cancers
Part of Cancer, Digestive system clinical trials.
This trial looks at whether some patients with gastrointestinal cancers that have specific genetic markers can safely avoid surgery after immunotherapy, or have a less invasive procedure, instead of the standard radical surgery. It aims to see which approach is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a gastrointestinal cancer, such as colorectal, stomach, or gastroesophageal junction cancer, that is adenocarcinoma or squamous cell carcinoma.
- Your tumor must have certain genetic features: either dMMR, MSI-H, or a POLE mutation. These are markers that may make the cancer more responsive to immunotherapy.
- You must have already received immunotherapy (immune checkpoint inhibitors) before this trial, either alone or in combination, to see how your tumor responds.
- You must be 18 years or older and have a good performance status (ECOG 0 or 1), meaning you are fully active or only restricted in physically strenuous activity.
- You must not have other active cancers within the past 5 years, and your cancer must not have spread to distant organs in a way that cannot be treated locally.
- You must be able to attend regular follow-up visits, including endoscopies and imaging scans, and be willing to sign a consent form if joining the prospective part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether people with certain types of colorectal or other gastrointestinal cancers can avoid or delay surgery and instead be monitored closely (watch-and-wait) after receiving immunotherapy. It aims to see if this approach can keep the cancer from coming back while improving quality of life.
This study looks at whether people with gastrointestinal cancers who respond well to targeted or immunotherapy can safely avoid surgery and keep their organs. It aims to see if close monitoring and follow-up instead of surgery is a good option.
This study looks at whether some patients with early-stage stomach, colon, or rectal cancers that are mismatch repair-deficient (a genetic feature making them more likely to respond to immunotherapy) can safely avoid surgery and instead be monitored closely after treatment with immunotherapy. It aims to confirm if this watch-and-wait approach is as effective and helps patients avoid major operations.
This trial is looking at whether giving extra treatment after surgery for stomach cancer can help lower the chance of it coming back. It is for people who had a specific kind of chemotherapy and immunotherapy before surgery and then had their stomach removed.
This trial tests whether adding a short course of radiation to a combination of chemotherapy and an immunotherapy drug (called a PD-1 inhibitor) before surgery helps shrink tumors and improve outcomes for people with upper stomach or gastroesophageal junction cancer.
This trial compares two different chemotherapy combinations given before radiation or surgery for high-risk locally advanced rectal cancer. One arm is more intense, and the other is standard. The goal is to see which works better at shrinking the tumor and possibly avoiding surgery.
Hear when a new Gastrointestinal Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.